Journals / Medicine Science / 2015 / Cilt: 4 Sayı: 3

Evaluation and Treatment of Anemia in Chronic Kidney Disease (Kronik Böbrek Hastalıklarında Aneminin Değerlendirilmesi ve Tedavisi )

Pages
2678–2693
Publication Date
2015-12-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Iron therapy is recommended in recent guidelines, in order to reduce the dose of ESA as well as delaying the uptake, in chronic kidney disease patients with TSAT <30% and ferritin <300 ng/mL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractAnemia is common in patients with chronic kidney disease.
📊
Key Findings & Data:The target hemoglobin value should be 11-12 g/dL.
💡
Conclusion & Impact:Iron therapy is recommended in recent guidelines, in order to reduce the dose of ESA as well as delaying the uptake, in chronic kidney disease patients with TSAT <30% and ferritin <300 ng/mL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kronik böbrek hastalığı · anemi · demir eksikliği

Özet

AbstractAnemia is common in patients with chronic kidney disease. Anemia is a major risk factor for cardiovascular disease and affects life quality. The reduction of renal erythropoietin synthesis is the essentially cause of anemia. Among other reasons can considered iron deficiency, inflammation, uremic toxins, hyperparathyroidism, hemolysis, reduction of erythrocyte survival and malnutrition. The reasons that lead to anemia should be investigated primarily in the treatment of anemia and treatment should be for the cause. Erythropoiesis-stimulating agents is the basis of the treatment of anemia in chronic kidney disease. ESA therapy should be initiated to patient after the ruled out other causes of anemia. The target hemoglobin value should be 11-12 g/dL. Iron deficiency must be evaluated before starting treatment with erythropoiesis stimulating agents and should be treated if any iron deficiency. Transferrin saturation (TSAT) and ferritin level is the most commonly used parameters in the evaluation of iron deficiency in chronic kidney disease in practice. Iron therapy should be given if serum ferritin concentrations <100 ng/ml and TSAT <20%. Iron therapy is recommended in recent guidelines, in order to reduce the dose of ESA as well as delaying the uptake, in chronic kidney disease patients with TSAT <30% and ferritin <300 ng/mL. Iron may be administered orally or parenterally in patients with iron deficiency. Parenteral administration should be preferred in hemodialysis patients. Correction of iron deficiency anemia reduces requirement for ESA. The treatment of anemia raises life quality of patients with chronic kidney diseases and is associated with a better prognosis. Keywords: Chronic kidney disease, anemia, iron deficiency anemia, erythropoietin

🔖

Cite This Article

AYGEN, B. (2015). Evaluation and Treatment of Anemia in Chronic Kidney Disease (Kronik Böbrek Hastalıklarında Aneminin Değerlendirilmesi ve Tedavisi ). Medicine Science, Cilt: 4 Sayı: 3, 2678–2693. https://ajindex.com/articles/1003241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Kaynaklar Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis. 2004;44(5 Suppl 2):27-33.
  2. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-10. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 1999;14 Suppl 51-50. Stevens P. Optimizing renal anaemia management--benefits of early referral and treatment. Nephrol Dial Transplant. 2005;20 Suppl 8viii22-26. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990;263(6):825-30.
  3. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE, Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7(5):763-73.
  4. Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68(4):1432-8. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279-335.
  5. Kdoqi, National Kidney F. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-145. Horl WH. A need for an individualized approach to end-stage renal disease patients. Nephrol Dial Transplant. 2002;17 Suppl 617-21.
  6. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984;25(2):437-44.
  7. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol. 2006;26(4):261-8.
  8. Ridley DM, Dawkins F, Perlin E. Erythropoietin: a review. J Natl Med Assoc. 1994;86(2):129-35.
  9. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008;36(12):1573-84.
  10. Sato Y, Yanagita M. Renal anemia: from incur